A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

This research study is about a new medicine called Trontinemab, which we hope could help people at risk of Alzheimer's disease. Alzheimer's is a condition that affects memory and thinking. Sometimes, before people start showing noticeable symptoms like memory loss, their bodies can show early signs of the disease. This study is for individuals who have these early signs but are still living their daily lives without any problems with their memory or thinking.

The main goal of the study is to see if Trontinemab can help stop or slow down the progression of Alzheimer's disease in these individuals. We want to find out if taking this medication can prevent them from developing milder memory problems (sometimes called mild cognitive impairment) or more advanced Alzheimer's disease later on. This is a crucial step in understanding if this new treatment could offer hope for preventing the disease.

Participants will be split into different groups. Some will receive Trontinemab, and others will receive a 'placebo' – a substance that looks exactly like the study medicine but contains no active drug. This allows researchers to compare the two groups fairly and see if Trontinemab truly makes a difference beyond what might happen naturally or with a dummy treatment. It's a 'Phase 3' study, which means it's one of the final and largest stages of research before a new medicine might be considered for wider use.